Article Text

AB0629 The efficacy of topical 0.05% cyclosporine a in patients of dry eye disease associated with sjÖgren’s syndrome
  1. H. Deveci1,
  2. S. Kobak2
  1. 1Ophtalmology, Manisa Hospital, Manisa
  2. 2Rheumatology, Sifa University, Faculty of Medicine, Izmir, Turkey


Background Sjögren’s syndrome (SS) is a chronic autoimmune disorder that involves exocrine glands and that may present alone (primary SS) or in association with another connective tissue disorder (secondary SS).

Objectives It was aimed to investigate the efficacy of topical 0.05% cyclosporine A in patients of dry eye disease associated with Sjogren’s syndrome.

Methods Twenty-six patients referred to our outpatient clinic and were diagnosed with Sjögren’s syndrome based on AECG classification criteria were included in this study. All of patients were evaluated by ophtalmologist and topical %0.05 cyclosporine A emulsion (Restasis; Allergan Inc, Irvine, California) were started. All patients were examined at 1.week and 1.month according to hyperemia, Shirmer’s test and tear break-up time. The subjective findings including burning-stinging, light sensitivity and pain complaints were also assessed.

Results 26 patients (19 female, 7 male; mean age, 47.5±10.2) were included in this study. At the first examination, burning-stinging(23patients), pain(24patients), light sensitivity(23patients) and hyperemia(24patients) were identified. All 26 patients responded well to treatment of topical %0.05 cyclosporine A emulsion. At 1.week and 1.month, there was an improvement in all of the following subjective and objective parameters. After treatment, were identified statistically significant recovery in all the subjective findings (burning-stinging, light sensitivity,pain and hyperemia) (p=0.0001). Also statistically significant recovery in all the objective findings (Schirmer’s test, tear break up time) (p=0.0001) were recorded.

Conclusions At the end of the 4-week follow-up process, it was resulted that topical 0.05% cyclosporine A may be an efficient treatment option in the patients of dry eye disease associated with Sjogren’s syndrome.

  1. Kanski JJ. Keratoconjunctivitis Sicca. Disorders of the conjunctiva. Butterwotrh-Heinemann International Edition (4th), Clinical Ophthalmology;1999:78-9.

  2. Douglas J. Rhee and Mark FP. Keratokonjunctivitis sicca. Cornea: The Wills Eye Manual; 1999:55-6.

  3. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye. A twenty-five-year review. Cornea 2000;19:644-9.

  4. Braida M, Knop J. Effect of cyclosporine A on the T-effector and T-supressor cell response in contact sensitivity. Immunology 1986;59:503-7.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.